{"result": "(\"entity\"<|>ABDELHAMID AS<|>PERSON<|>Abdelhamid AS is an author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>BROWN TJ<|>PERSON<|>Brown TJ is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>BRAINARD JS<|>PERSON<|>Brainard JS is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>BISWAS P<|>PERSON<|>Biswas P is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>THORPE GC<|>PERSON<|>Thorpe GC is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>MOORE HJ<|>PERSON<|>Moore HJ is a co-author of a study on omega-3 fatty acids for cardiovascular disease prevention.)\n##\n(\"entity\"<|>FERRANNINI E<|>PERSON<|>Ferrannini E is an author of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.)\n##\n(\"entity\"<|>MUSCELLI E<|>PERSON<|>Muscelli E is a co-author of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.)\n##\n(\"entity\"<|>FRASCERRA S<|>PERSON<|>Frascerra S is a co-author of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.)\n##\n(\"entity\"<|>FOGARI R<|>PERSON<|>Fogari R is an author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>ZOPPI A<|>PERSON<|>Zoppi A is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>MALAMANI GD<|>PERSON<|>Malamani GD is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>LAZZARI P<|>PERSON<|>Lazzari P is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>ALBONICO B<|>PERSON<|>Albonico B is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>CORRADI L<|>PERSON<|>Corradi L is a co-author of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.)\n##\n(\"entity\"<|>REDON J<|>PERSON<|>Redon J is an author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>LIAO Y<|>PERSON<|>Liao Y is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>LOZANO JV<|>PERSON<|>Lozano JV is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>MIRALLES A<|>PERSON<|>Miralles A is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>PASCUAL JM<|>PERSON<|>Pascual JM is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>COOPER RS<|>PERSON<|>Cooper RS is a co-author of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.)\n##\n(\"entity\"<|>SARAFIDIS PA<|>PERSON<|>Sarafidis PA is an author of a study on the metabolic effects of beta blockers in the treatment of hypertension.)\n##\n(\"entity\"<|>BAKRIS GL<|>PERSON<|>Bakris GL is a co-author of a study on the metabolic effects of beta blockers in the treatment of hypertension.)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>BROWN TJ<|>Abdelhamid AS and Brown TJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>BRAINARD JS<|>Abdelhamid AS and Brainard JS are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>BISWAS P<|>Abdelhamid AS and Biswas P are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>THORPE GC<|>Abdelhamid AS and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>ABDELHAMID AS<|>MOORE HJ<|>Abdelhamid AS and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>BRAINARD JS<|>Brown TJ and Brainard JS are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>BISWAS P<|>Brown TJ and Biswas P are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>THORPE GC<|>Brown TJ and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BROWN TJ<|>MOORE HJ<|>Brown TJ and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BRAINARD JS<|>BISWAS P<|>Brainard JS and Biswas P are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BRAINARD JS<|>THORPE GC<|>Brainard JS and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BRAINARD JS<|>MOORE HJ<|>Brainard JS and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BISWAS P<|>THORPE GC<|>Biswas P and Thorpe GC are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>BISWAS P<|>MOORE HJ<|>Biswas P and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>THORPE GC<|>MOORE HJ<|>Thorpe GC and Moore HJ are co-authors of a study on omega-3 fatty acids for cardiovascular disease prevention.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>MUSCELLI E<|>Ferrannini E and Muscelli E are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>FRASCERRA S<|>Ferrannini E and Frascerra S are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>FOGARI R<|>Ferrannini E and Fogari R are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>ZOPPI A<|>Ferrannini E and Zoppi A are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>MALAMANI GD<|>Ferrannini E and Malamani GD are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>LAZZARI P<|>Ferrannini E and Lazzari P are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>ALBONICO B<|>Ferrannini E and Albonico B are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FERRANNINI E<|>CORRADI L<|>Ferrannini E and Corradi L are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>FRASCERRA S<|>Muscelli E and Frascerra S are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>FOGARI R<|>Muscelli E and Fogari R are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>ZOPPI A<|>Muscelli E and Zoppi A are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>MALAMANI GD<|>Muscelli E and Malamani GD are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>LAZZARI P<|>Muscelli E and Lazzari P are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>ALBONICO B<|>Muscelli E and Albonico B are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>MUSCELLI E<|>CORRADI L<|>Muscelli E and Corradi L are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>FOGARI R<|>Frascerra S and Fogari R are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>ZOPPI A<|>Frascerra S and Zoppi A are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>MALAMANI GD<|>Frascerra S and Malamani GD are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>LAZZARI P<|>Frascerra S and Lazzari P are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>ALBONICO B<|>Frascerra S and Albonico B are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FRASCERRA S<|>CORRADI L<|>Frascerra S and Corradi L are co-authors of a study on metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>ZOPPI A<|>Fogari R and Zoppi A are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>MALAMANI GD<|>Fogari R and Malamani GD are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>LAZZARI P<|>Fogari R and Lazzari P are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>ALBONICO B<|>Fogari R and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>FOGARI R<|>CORRADI L<|>Fogari R and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>MALAMANI GD<|>Zoppi A and Malamani GD are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>LAZZARI P<|>Zoppi A and Lazzari P are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>ALBONICO B<|>Zoppi A and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ZOPPI A<|>CORRADI L<|>Zoppi A and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>MALAMANI GD<|>LAZZARI P<|>Malamani GD and Lazzari P are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>MALAMANI GD<|>ALBONICO B<|>Malamani GD and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>MALAMANI GD<|>CORRADI L<|>Malamani GD and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>LAZZARI P<|>ALBONICO B<|>Lazzari P and Albonico B are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>LAZZARI P<|>CORRADI L<|>Lazzari P and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>ALBONICO B<|>CORRADI L<|>Albonico B and Corradi L are co-authors of a study on urinary albumin excretion and nocturnal blood pressure in hypertensive patients with type II diabetes mellitus.<|>8)\n##\n(\"relationship\"<|>REDON J<|>LIAO Y<|>Redon J and Liao Y are co-authors of a study on ambulatory blood pressure and microalbuminuria in essential hypertension.<|>8)\n##\n(\"relationship\"<|>REDON J<|>LOZANO JV<|>Redon J and Lozano", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ácido α-linolénico (ALA), una grasa que\n         se  encuentra en los alimentos              de   origen vegetal,      el ácido eicosapentaenoico (EPA)                y  el\n         ácido docosahexaenoico (DHA), ambos derivados del pescado. El aumento de EPA y DHA                                                  59  Señale la afirmación falsa en relación con los efectos de los fármacos para el\n         (w-3) tiene poco o ningún efecto sobre la muerte y los eventos cardiovasculares (evidencia                                              tratamiento de la DM2:\n         de alta calidad) y probablemente logra poco o ningún cambio en la muerte cardiovascular,                                                A. La metformina inhibe la gluconeogénesis hepática.\n         la muerte o los eventos coronarios, el accidente cerebrovascular o las alteraciones cardía-\n         cas (evidencia de calidad moderada).                                                                                                    B. La pioglitazona reduce los triglicéridos.\n         El uso de gliflozinas (iSGLT2) conlleva un aumento de las concentraciones de glucagón.                                                  C. Las sulfonilureas actúan a través de la unión al receptor IRS-1 de la membrana\n                                                                                                                                                     plasmática de la célula β.\n         La presencia de microalbuminuria es un marcador de la presencia de valores más altos de                                                 D.  Los inhibidores de DPP4 producen un aumento de GLP1 y GIP endógeno.\n         presión arterial durante un período de 24 h.\n         Referencias:                                                                                                                            COMENTARIO\n         • Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary\n           prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018;11:CD003177.\n         • Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic      La metformina reduce la producción hepática de glucosa mediante la inhibición de la glu-\n           patients. J Clin Invest. 2014;124(2):499-508.                                                                                         coneogénesis y la glucogenólisis al tiempo que aumenta la síntesis intracelular de glu-\n         • Fogari R, Zoppi A, Malamani GD, Lazzari P, Albonico B, Corradi L. Urinary albumin excretion and nocturnal blood pressure\n           in hypertensive patients with type II diabetes mellitus. Am J Hypertens. 1994;7(9 Pt 1):808-13.                                       cógeno al actuar sobre la glucógeno sintetasa. En el músculo incrementa la sensibilidad\n         • Redon J, Liao Y, Lozano JV, Miralles A, Pascual JM, Cooper RS. Ambulatory blood pressure and microalbuminuria in essential            a la insulina mejorando la captación de glucosa periférica y su utilización, ya que aumenta\n           hypertension: role of circadian variability. J Hypertens. 1994;12(8):947-53.\n         • Sarafidis PA, Bakris GL. Do the metabolic effects of beta blockers make them leading or supporting antihypertensive agents            la capacidad de transporte de todos los tipos de transportadores de membrana de glucosa\n           in the treatment of hypertension? J Clin Hypertens (Greenwich). 2006;8(5):351-6; quiz 357-8. PubMed PMID: 16687944.                   (GLUT) conocidos. Por último, retrasa la absorción intestinal de glucosa.\n                                                                                                                                                 Los efectos de la pioglitazona se producen a través de una reducción de la resistencia a la\n     58  Con respecto a la antiagregación en los pacientes con diabetes, es cierto que:                                                          insulina, lo que conlleva un perfil lípido más favorable, con reducción de triglicéridos y au-\n                                                                                                                                                 mento del colesterol HDL. Parece que la pioglitazona ejerce su acción al activar receptores\n         A. El antiagregante de elección es el clopidogrel.                                                                                      nucleares específicos (receptor γ activado por un proliferador de peroxisoma), produciendo\n         B. Se ofrecerá tratamiento a los pacientes en prevención secundaria.                                                                    un aumento de la sensibilidad a la insulina de las células del hígado, del tejido adiposo y del\n         C. La dosis correcta de ácido acetilsalicílico es de 250 mg en dosis única.                                                             músculo esquelético en animales. Se ha demostrado que el tratamiento con pioglitazona\n         D.  Todas las respuestas anteriores son falsas.                                                                                         reduce la producción de glucosa hepática y aumenta la utilización de glucosa periférica en\n                                                                                                                                                 casos de resistencia a la insulina.\n                                                                                                                                                 Tanto las sulfonilureas como las glinidas basan su mecanismo de acción en un aumento\n         COMENTARIO                                                                                                                              de la secreción       de insulina por las células\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}